Cadila Healthcare up 1% on USFDA final approval for Allopurinol tablets

Myth 3: Everyone who has a mental illness needs medication to manage symptoms | Bulthuis says no two patients are the same. While medicines can help manage symptoms, there are some people with mental illness who do not require medication. For others, medicine is essential for recovery. (Representative image)

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Share price of Cadila Healthcare rose 1 percent intraday Monday on USFDA approval for Allopurinol tablets.

Zydus Cadila has received final approval from the USFDA to market Allopurinol Tablets USP, 100 mg and 300 mg.

The drug is used to treat major depression and will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

The group has now more than 160 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

The meeting of the board of directors of the company will be held on November 14, 2017 to consider apart from other agenda items to approve the unaudited financial results for the quarter / half year ended on September 30, 2017.

The trading window will remain closed from November 3, 2017 to November 16, 2017 for all directors and designated officers of the company.

At 09:18 hrs Cadila Healthcare was quoting at Rs 505.05, up Rs 3.65, or 0.73 percent.

The share touched its 52-week high Rs 558 and 52-week low Rs 342 on 12 June, 2017 and 26 December, 2016, respectively.